At the time of writing, Pacira BioSciences Inc [PCRX] stock is trading at $25.18, up 1.66%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PCRX shares have gain 4.09% over the last week, with a monthly amount glided 9.15%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Pacira BioSciences Inc [NASDAQ: PCRX] stock has seen the most recent analyst activity on December 09, 2025, when Barclays initiated its Equal Weight rating and assigned the stock a price target of $27. On July 25, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $30 on the stock. Truist upgraded its rating to a Hold and increased its price target to $25 on January 30, 2025. Truist downgraded its rating to a Sell and reduced its price target to $8 on August 13, 2024. RBC Capital Mkts downgraded its rating to Sector Perform for this stock on August 12, 2024, and downed its price target to $14. In a note dated August 12, 2024, Raymond James downgraded an Mkt Perform rating on this stock.
For the past year, the stock price of Pacira BioSciences Inc fluctuated between $18.17 and $27.64. Currently, Wall Street analysts expect the stock to reach $27 within the next 12 months. Pacira BioSciences Inc [NASDAQ: PCRX] shares were valued at $25.18 at the most recent close of the market. An investor can expect a potential return of 7.23% based on the average PCRX price forecast.
Analyzing the PCRX fundamentals
According to Pacira BioSciences Inc [NASDAQ:PCRX], the company’s sales were 716.79M for trailing twelve months, which represents an 6.49% jump. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at 0.06%, Pretax Profit Margin comes in at 0.06%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.04 and Total Capital is 0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.71 points at the first support level, and at 24.25 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.48, and for the 2nd resistance point, it is at 25.79.
Ratios To Look Out For
It is important to note that Pacira BioSciences Inc [NASDAQ:PCRX] has a current ratio of 5.26. Further, the Quick Ratio stands at 3.78, while the Cash Ratio is 1.38. Considering the valuation of this stock, the price to sales ratio is 1.51, the price to book ratio is 1.49 and price to earnings (TTM) ratio is 56.44.
Transactions by insiders
Recent insider trading involved Cross Shawn, Officer, that happened on Dec 10 ’25 when 9104.0 shares were purchased. Officer, Cross Shawn completed a deal on Dec 09 ’25 to buy 15896.0 shares. Meanwhile, Chief Medical Officer SLONIN JONATHAN sold 3960.0 shares on Nov 17 ’25.
